Financial reports
ARS
2022 FY
Annual report to shareholders
30 Nov 23
10-Q
2023 Q3
Quarterly report
15 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Entry into a Material Definitive Agreement
22 Mar 24
8-K
Changes in Registrant's Certifying Accountant
12 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
29 Dec 23
8-K
Departure of Directors or Certain Officers
28 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
2 Oct 23
8-K
Material Modifications to Rights of Security Holders
15 Sep 23
8-K
Amendments to Articles of Incorporation or Bylaws
15 Aug 23
8-K
Petros Pharmaceuticals Announces Capital Raise of $15 million
13 Jul 23
8-K
Petros Pharmaceuticals Announces Reverse Stock Split
30 Nov 22
8-K
Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update
15 Nov 22
Registration and prospectus
424B3
Prospectus supplement
19 Sep 23
S-3/A
Shelf registration (amended)
15 Sep 23
S-3
Shelf registration
11 Aug 23
D
$30.00 mm in equity / options / securities to be acquired, sold $30.00 mm, 15 investors
21 Jul 23
S-8
Registration of securities for employees
22 Dec 22
POS AM
Prospectus update (post-effective amendment)
14 Oct 22
424B3
Prospectus supplement
14 Jan 22
S-1
IPO registration
6 Jan 22
D
$8.32M in equity / options / securities to be acquired, sold $2.2M, 12 investors
3 Jan 22
424B5
Prospectus supplement for primary offering
23 Dec 21
Other
EFFECT
Notice of effectiveness
19 Sep 23
CORRESP
Correspondence with SEC
15 Sep 23
UPLOAD
Letter from SEC
16 Aug 23
EFFECT
Notice of effectiveness
21 Oct 22
EFFECT
Notice of effectiveness
18 Jan 22
CORRESP
Correspondence with SEC
12 Jan 22
CORRESP
Correspondence with SEC
12 Jan 22
UPLOAD
Letter from SEC
12 Jan 22
EFFECT
Notice of effectiveness
20 Dec 21
CORRESP
Correspondence with SEC
15 Dec 21
Ownership